Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) insider Namrata Saroj sold 35,370 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $6.55, for a total value of $231,673.50. Following the sale, the insider owned 220,522 shares in the company, valued at approximately $1,444,419.10. This represents a 13.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Ocular Therapeutix Stock Up 0.8%
Shares of NASDAQ OCUL opened at $6.66 on Thursday. The business has a fifty day simple moving average of $8.17 and a 200 day simple moving average of $8.96. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.03 and a current ratio of 13.10. Ocular Therapeutix, Inc. has a one year low of $6.00 and a one year high of $16.44.
Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last issued its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.06). Ocular Therapeutix had a negative return on equity of 56.26% and a negative net margin of 648.64%. The firm had revenue of $12.87 million during the quarter, compared to the consensus estimate of $14.27 million. During the same period last year, the business earned ($0.38) earnings per share. The firm’s revenue for the quarter was down 11.5% compared to the same quarter last year. As a group, equities research analysts expect that Ocular Therapeutix, Inc. will post -1.49 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
OCUL has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, October 15th. Chardan Capital reissued a “buy” rating and issued a $23.00 target price on shares of Ocular Therapeutix in a research note on Friday, October 2nd. UBS Group started coverage on shares of Ocular Therapeutix in a research report on Sunday, October 11th. They issued a “buy” rating and a $14.00 price target for the company. Wall Street Zen upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $23.83.
Get Our Latest Stock Analysis on Ocular Therapeutix
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Private Advisor Group LLC acquired a new stake in shares of Ocular Therapeutix during the 3rd quarter worth about $130,000. CenterBook Partners LP acquired a new position in Ocular Therapeutix in the third quarter valued at about $233,000. Kraematon Investment Advisors Inc. boosted its position in Ocular Therapeutix by 6.9% in the third quarter. Kraematon Investment Advisors Inc. now owns 117,517 shares of the biopharmaceutical company’s stock valued at $901,000 after buying an additional 7,550 shares in the last quarter. Commonwealth Equity Services LLC boosted its position in Ocular Therapeutix by 8.1% in the third quarter. Commonwealth Equity Services LLC now owns 20,992 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 1,575 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Ocular Therapeutix during the third quarter worth about $86,000. 59.21% of the stock is owned by institutional investors.
About Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.
Featured Articles
- Five stocks we like better than Ocular Therapeutix
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.
